Maria Orr

2.4k total citations · 1 hit paper
16 papers, 1.8k citations indexed

About

Maria Orr is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maria Orr has authored 16 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maria Orr's work include PARP inhibition in cancer therapy (9 papers), Cancer Genomics and Diagnostics (8 papers) and BRCA gene mutations in cancer (6 papers). Maria Orr is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), Cancer Genomics and Diagnostics (8 papers) and BRCA gene mutations in cancer (6 papers). Maria Orr collaborates with scholars based in United Kingdom, United States and Israel. Maria Orr's co-authors include Darren Hodgson, Brian Dougherty, Jonathan A. Ledermann, J. Carl Barrett, Anitra Fielding, Stuart Spencer, Charlie Gourley, Tamar Safra, Ronnie Shapira‐Frommer and Werner Meier and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Maria Orr

16 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Orr United Kingdom	12	1.3k	794	702	473	363	16	1.8k
Yvette Drew United Kingdom	22	1.8k 1.3×	1.4k 1.7×	625 0.9×	333 0.7×	233 0.6×	68	2.3k
Kathryn Alsop Australia	14	816 0.6×	660 0.8×	701 1.0×	571 1.2×	385 1.1×	24	1.5k
Jacqui Rowbottom United Kingdom	10	1.2k 0.9×	567 0.7×	271 0.4×	215 0.5×	321 0.9×	14	1.6k
Céline Jacquemont United States	13	994 0.7×	1.2k 1.5×	202 0.3×	347 0.7×	293 0.8×	22	1.6k
Janneke E. Jaspers Netherlands	15	1.5k 1.2×	1.4k 1.8×	154 0.2×	388 0.8×	284 0.8×	17	2.0k
Andrea E. Wahner Hendrickson United States	15	839 0.6×	633 0.8×	405 0.6×	113 0.2×	157 0.4×	55	1.3k
Daniel J. Farrugia United States	11	787 0.6×	942 1.2×	149 0.2×	442 0.9×	375 1.0×	17	1.4k
Christin Whalen United States	14	785 0.6×	487 0.6×	642 0.9×	136 0.3×	74 0.2×	22	1.1k
Ioannis Assiotis United Kingdom	12	699 0.5×	1.0k 1.3×	110 0.2×	274 0.6×	244 0.7×	14	1.4k
Niklas Loman Sweden	2	1.0k 0.8×	774 1.0×	104 0.1×	463 1.0×	323 0.9×	5	1.3k

Countries citing papers authored by Maria Orr

Since Specialization

Citations

This map shows the geographic impact of Maria Orr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Orr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Orr more than expected).

Fields of papers citing papers by Maria Orr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Orr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Orr. The network helps show where Maria Orr may publish in the future.

Co-authorship network of co-authors of Maria Orr

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Orr. A scholar is included among the top collaborators of Maria Orr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Orr. Maria Orr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Golan, Talia, Hedy L. Kindler, Philipp Schatz, et al.. (2021). Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).. Journal of Clinical Oncology. 39(3_suppl). 420–420. 1 indexed citations

Hodgson, Darren, Brian Dougherty, Zhongwu Lai, et al.. (2018). Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer. 119(11). 1401–1409. 167 indexed citations

Hodgson, Darren, Gershon Y. Locker, Zhongwu Lai, et al.. (2018). Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer. Annals of Oncology. 29. viii25–viii26. 10 indexed citations

Dougherty, Brian, Zhongwu Lai, Darren Hodgson, et al.. (2017). Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget. 8(27). 43653–43661. 64 indexed citations

Jänne, Pasi A., Ian C. P. Smith, Gael McWalter, et al.. (2015). Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. British Journal of Cancer. 113(2). 199–203. 59 indexed citations

Hodgson, Darren, Brian Dougherty, Zefeng Lai, et al.. (2015). 435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. European Journal of Cancer. 51. S90–S90. 20 indexed citations

Dougherty, Brian, Zhongwu Lai, Jonathan A. Ledermann, et al.. (2015). Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition. Cancer Research. 75(15_Supplement). 611–611. 3 indexed citations

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations

Donald, Emma, Gillian Ellison, Sarah R. Bujac, et al.. (2014). Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics. 16(3). 343–349. 38 indexed citations

10.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 15(8). 852–861. 1060 indexed citations breakdown →

11.

Sherwood, James, Susanne Müller, Maria Orr, M. Ratcliffe, & Jill Walker. (2014). Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour. PLoS ONE. 9(6). e100566–e100566. 9 indexed citations

12.

Hagan, Suzanne, Maria Orr, & Brendan Doyle. (2013). Targeted therapies in colorectal cancer—an integrative view by PPPM. The EPMA Journal. 4(1). 3–3. 65 indexed citations

13.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2013). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).. Journal of Clinical Oncology. 31(15_suppl). 5505–5505. 31 indexed citations

14.

Ellison, Gillian, Emma Donald, Gael McWalter, et al.. (2010). A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. Journal of Experimental & Clinical Cancer Research. 29(1). 132–132. 132 indexed citations

15.

Hodgson, Darren, Robert Wellings, Maria Orr, et al.. (2010). Circulating tumour-derived predictive biomarkers in oncology. Drug Discovery Today. 15(3-4). 98–101. 23 indexed citations

16.

Board, Ruth, Gillian Ellison, Maria Orr, et al.. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. British Journal of Cancer. 101(10). 1724–1730. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact